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Abstract 
This paper reviews some current methods for the in vivo assessment of local 
cutaneous bioavailability in humans after topical drug application. After an 
introduction discussing the importance of local drug bioavailability assessment and 
the limitations of the predictive calculations, the focus turns to the relevance of 
experimental studies. The available techniques are then reviewed in detail, with 
particular emphasis on the tape stripping and microdialysis methodologies. Other less 
developed techniques, including the skin biopsy, suction blister, follicle removal and 
confocal Raman spectroscopy techniques are also described. 
Keywords: Cutaneous bioavailability, cutaneous drug concentration, tape stripping, 
microdialysis, dermatopharmacokinetics. 
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Introduction 
Skin is the largest organ of the human body and is composed of three readily 
distinguishable layers: (a) the stratum corneum (SC), which is the outermost part of 
the epidermis, (b) the living epidermis, and (c) the dermis penetrated by a highly 
complex network of capillaries involved in the removal of drugs from the skin into the 
systemic circulation. In addition, several pilosebaceous and sweat glands are 
dispersed throughout the skin, in various numbers and size, depending on body site. 
The SC is well-recognized as a heterogeneous two-compartment system of flattened 
keratinized cells embedded in a multilamellar lipid matrix mainly composed of neutral 
lipids and ceramides (1-4). It has a thickness of about 10 μm (5-7) and is composed of 
about 20 cell layers (5). Its main homeostatic functions are restriction of excessive 
water loss to the external environment, moisture retention, cell cohesion and 
desquamation. In addition, SC is considered to be the rate-controlling membrane for 
transport of xenobiotics across the skin (although, for very lipophilic molecules, 
partitioning into the more hydrophilic viable tissue may constitute the greater 
resistance (2,8). Therefore, topical skin bioavailability assessment of xenobiotics is 
essential for both the (trans)dermal delivery of pharmacological active drugs and from 
a toxicological point of view (9). 
For systemically delivered oral products, bioavailability is typically defined as 
the rate and extent at which a drug reaches the general circulation from an 
administered dosage form (10). Dermatological drug products include a broad array of 
preparations which are designed to exert a local effect in diseased skin following 
topical application on the skin surface. The objective is to maximize drug 
concentration at the site of action within the skin with, ideally, a minimal systemic 
uptake (11). Thus, systemic availability may not properly reflect local cutaneous 
bioavailability (as it does for transdermal products, on the other hand, which are 
designed to deliver drug into the systemic circulation). Moreover, topical doses tend 
to be so small (typically 2-5 mg of product/cm2) that serum and/or urine 
concentrations are often undetectable using conventional assay techniques (12).  A 
further complicating factor is the lack of knowledge of the drug concentration needed 
at the skin target site (with the exception of antifungal agents whose target site is the 
SC surface). Topical bioavailability has been more rigorously defined the 
bioavailability as the temporal pattern of free drug concentration at the target site (the 
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so-called C* concept (10)), but the value of this approach remains largely theoretical 
due to the difficulty of quantifying drug within the skin. 
What options are available, then, for assessment of topical bioavailability and 
bioequivalence?  Although a drug’s permeability coefficient through human skin can 
be estimated, for example, from the molecular weight and octanol-water partition 
coefficient (13), this information is not sufficient to estimate topical bioavailability. 
The algorithms available are able to approximate a value for the maximum drug flux 
across the skin, but cannot quantify the potential impact of particular vehicles (or 
vehicle constituents) on skin barrier function (14).  Equally, these calculations assume 
that the thermodynamic activity of the drug remains constant during the application 
period, a situation which does not pertain, of course, when one or more formulation 
component is volatile (15) or the dose administered is very small (i.e., a finite dose 
situation). 
It follows that an experimental approach is necessary, and the objective of this 
review is to evaluate different techniques currently under consideration.  We begin 
with a discussion of the different procedures which are accepted by the regulatory 
authorities at this time, and which contribute to the approval of innovative, and/or 
generic, topical drug products. 
Current options for topical bioavailability / bioequivalence 
assessment  
As mentioned above, for topical dermatological products, pharmacokinetic 
measurements in blood, plasma or urine are usually not feasible because of the very 
low concentrations achieved in these typical sampling compartments.  There is also 
debate as to whether measurable levels in the blood (when detectable), for example, 
are relevant to local, topical drug bioavailability.  On the other hand, the cumulative 
amount of drug reaching the systemic circulation is pertinent with respect to potential 
toxicity and may indicate the need to limit topical application to avoid undesirable 
side-effects. 
For certain topical drugs, specifically the corticosteroids, pharmacodynamic 
measurements represent an accepted approach with which to establish bioequivalence 
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between different formulations (and are used, as well, in the development of new 
chemical entities in the same therapeutic class).  These drugs produce skin blanching 
at the site of application and this response has been correlated with clinical efficacy 
(16). The original Stoughton-McKenzie vasoconstriction assay (17) employed visual 
evaluation of the degree of blanching by trained observers. As this approach is rather 
subjective (18), it is now considered sensible to use a chromameter to quantify the 
blanching response (19-22). This method has been reviewed in detail elsewhere (20).  
While the advantages of the vasoconstriction assay for topical steroids are clear, 
the approach has the obvious limitation that it cannot be applied to all drugs.  Indeed, 
the literature contains very few other examples in which pharmacologic response has 
been used to assess topical drug availability.  Evaluation of vasodilatation provoked 
by nicotinic acid esters, and its inhibition by anti-inflammatory drugs, has been 
performed using laser Doppler velocimetry and chromametry (23-27).  The reduction 
in erythema induced by topical ibuprofen has been correlated with drug levels in the 
epidermis (27).  Equally, topical retinoids have been shown to provoke increases in 
transepidemal water loss in a time- and dose-dependent fashion (28-30), although the 
generality of this effect has not been established (29). 
It follows that, at the present time, topical drug bioavailability and 
bioequivalence must be assessed via clinical studies, which are typically costly and 
time-consuming (31); regulatory agencies have therefore been seeking alternative 
methodologies, especially for bioequivalence studies to ease the burden on those 
attempting to commercialize useful products at competitive prices.  While much 
debate has centered on the potential of different in vitro techniques, in particular the 
use of Franz diffusion cell studies to compare different formulations, these methods 
have not been accepted as useful contributors to the overall determination of 
bioavailability and bioequivalence.  Currently, the relevance, reliability and 
reproducibility of the in vitro approach have not been demonstrated to the level 
necessary for the regulatory bodies; major concerns centre around the source and 
supply of human skin tissue, the ‘quality-control’ of the experiments, in general, and 
the absence of an effective clearance mechanism for drugs (especially lipophilic 
species) from the membrane.  Only for demonstrating the benign effect of minor 
formulation changes are in vitro experiments, using model, polymer membranes, 
authorized by, for example, the U.S. Food & Drug Administration. 
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Nevertheless, there remains a real need to develop valid, effective and 
economical approaches with which to measure topical drug bioavailability, not least 
for the evaluation of bioequivalence when generic products are submitted for 
marketing approval.  The remainder of this review examines, primarily, two 
methodologies currently under close examination for the measurement of topical 
bioavailability and bioequivalence: namely, the tape-stripping and microdialysis 
techniques. 
Tape stripping 
Tape stripping involves sequentially removing microscopic layers (typically 0.5­
1 μm) of stratum corneum. It is usually performed by placing an adhesive tape-strip 
onto the skin surface, followed by gentle pressure to ensure a good contact, and 
subsequently removal by a sharp upward movement. The procedure is relatively 
painless and non invasive, given that only dead cells (corneocytes) embedded in their 
lipid matrix are removed.  Even if skin stripping remains a form of environmental 
insult, a homeostatic repair response in the epidermis is rapidly elicited (32) which 
results in rapid restoration of barrier function after 36 hours (33).  
Tape stripping is used in various fields of cutaneous biology: for example, to 
evaluate the barrier function (34), to investigate dermatopathologies such as 
inflammatory or neoplastic disorders or xerotic conditions (35), to monitor gene 
expression (36,37), to investigate pH profiles (38), to evaluate animal skin as a 
surrogate for human skin (39), to induce Toll-like receptor 9 expression (40) and so 
on (41). In dermatopharmacology, tape stripping is used to assess cutaneous drug or 
excipient levels in the skin after topical dermatological treatment, either in the 
removed tape-strips, or directly in the tape-stripped skin.  It follows that tape stripping 
is a particularly useful technique to assess the local bioavailability of drugs whose 
target site is the SC itself (such as antifungal agents (43-46), UVA/UVB filters (47­
51) or antiseptics (52). 
The tape stripping technique may also offer a real alternative for local 
bioavailability and/or bioequivalence assessment of topically applied dermatological 
agents whose target is the underlying viable tissues. As the SC is usually the principal 
resistance to the penetration of topically applied compounds (4), it has been argued 
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that drug levels in the barrier should be correlated with those attained in the 
underlying, viable components of the skin, i.e., the sites at which many 
dermatological diseases are manifest. 
This hypothesis was tested, but only partially validated, by Rougier et al. (53­
56). In both animal models and human volunteers, for a range of compounds (mostly 
low molecular weight, low lipophilicity) delivered from several different 
formulations, the amount of active in the SC after a 30-minute application, and 
subsequent removal of any remaining vehicle, was determined by tape-stripping.  At a 
contra-lateral position, the same 30-minute application and cleaning procedure was 
adopted but, rather than tape-stripping the SC, the penetration of chemical taken up 
into the skin was quantified by its urinary excretion over the next 4 days. Good 
correlation between the two measurements was achieved (see Figure 1) suggesting the 
value of the tape-stripping approach for a simple and rapid determination of potential 
systemic exposure. However, the experiment only solves part of the bioavailability 
challenge: it provides a measurement of the extent of absorption but gives no 
information on rate.  As such, in its originally developed form, to so-called ‘Rougier 
technique’ is not suitable for regulatory use. 
An alternative strategy to test the hypothesis is to demonstrate correlation 
between drug levels measured in the SC by tape-stripping and a pharmacodynamic 
effect in the skin. This has been accomplished in some necessarily limited studies 
using (a) hydrocortisone (57) and betamethasone diproprionate (16,20), the 
pharmacological activity of which was assessed by skin blanching, (b) miconazole 
and ketoconazole, the efficacy of which against C.Albicans in vitro was determined 
(42), and (c) iododeoxyuridine, for which clinical efficacy in reducing lesion severity 
was evaluated (58). Ultimately, of course, these types of validation studies are 
essential if a tape-stripping approach is to be adopted for routine bioavailability and 
bioequivalence assessment. For the moment, however, the field is (appropriately) 
examining how to optimize the tape-stripping procedure so as to extract the maximum 
information from the experiment in the most efficient manner possible.  These 
advances are now discussed in detail. 
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Method development and optimization 
Sequential tape-stripping of the stratum corneum allows horizontal fractions of 
the membrane to be obtained. The tape-strips must then be extracted to recover and 
quantify the absorbed drug. Local bioavailability may be assessed either from the 
combined tape strips, or from the individual tape-strips.  The method of quantification 
depends, of course, on the nature of the drug and the amount present on the tape-
strips. Various approaches have been used ranging from UV-VIS spectrophotometry 
(59) to the more ubiquitous HPLC (with UV, fluorescence, or even mass 
spectrophotometric detection), gas chromatography (60-62), scintillation counting 
(42,57,63) and infrared spectroscopy (64-67). The key criteria are that the extraction 
process does not degrade the drug, that it is efficient and reproducible, and that it is 
free from interference from components of the SC and/or the tape adhesive. 
Quantification of the drug in the combined tape-strips enables the total amount in the 
stratum corneum to be determined.  
After much discussion (31,68-71), a draft guidance was published by the U.S. 
Food & Drug Administration (FDA) in 1998 (21) in which the general procedures for 
conducting a bioavailability/bioequivalence study were described.  Briefly, the 
guidance proposed the following steps: 
1. 	 After application of a drug product for a given application time, excess 
formulation was to be removed by an appropriate (but not specified) 
procedure. 
2. 	 Two sequential tape-strips of the SC were to be taken and discarded, the 
guidance arguing that material located on these samples had not been, 
and would not be, absorbed. 
3. 	 Subsequently, 10 strips from the application site were to be made, 
combined and extracted with a suitable solvent. 
4. 	 The entire process was to be performed at multiple sites following 
different times of application (absorption phase, Figure 2a) and different 
periods between the longest application time and the time at which 
stripping was performed (elimination phase, Figure 2b). 
5. 	 The total amount of drug in the SC was then to be displayed as a 
function of time as a so-called “dermatopharmacokinetic” (DPK) profile, 
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characterized by a maximum amount, the time at which this maximum 
was achieved, and an ‘area-under-the-curve’ (Figure 3). 
6. 	 Simultaneous comparison of two formulations of the same drug would 
allow an assessment of local bioequivalence using the representative 
DPK parameters. 
Although useful as a ‘jumping-off’ point, the guidance was open to a number of 
criticisms, and exposed some clear flaws.  In brief, many of these problems have now 
been recognized, but not fully resolved, the document has therefore been withdrawn 
and, at the time of writing, the possibility of a refined version being developed is 
under examination.  Among the weaknesses of the original guidance, one may cite, in 
particular: 
(a)	 The timing of the tape-stripping procedures during the absorption and 
elimination phases is not clearly delineated and (apart from trial-and­
error) no rational approach to their determination is offered. 
(b) 	 The number of tape-stripping procedures is considerable, rendering a 
DPK evaluation onerous in terms of the work involved (despite the fact 
that ‘pooling’ tapes for analysis does partly reduce this burden). 
(c) 	 The unvalidated discarding of information from the first two tape-strips 
has never been subjected to rigorous examination; indeed, it has been 
argued that these data are relevant to a complete bioavailability 
assessment (46). 
(d) 	 Ten tape-strips do not remove the same amount of SC from all subjects 
(or even, potentially, within a subject, especially if one of the 
formulations being compared contains an excipient which weakens SC 
cohesivity).  As a result, drug will be measured in different ‘volumes’ of 
the matrix, rendering comparisons between different treatments/subjects 
essentially meaningless. 
Nevertheless, there have been some reports of success using the DPK 
procedure as outlined in the FDA guidance (or at least part of it); one particularly 
good example showed a correlation between both the area-under-the-curve and 
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 maximum concentration parameters and the clinical efficacy of tretinoin gels (Figure 
4) (72).  Less encouraging, and ultimately responsible for the DPK guidance’s 
withdrawal, was an inter-laboratory comparative study (again using tretinoin) that 
resulted in diametrically opposite conclusions about the bioequivalence of different 
formulations (73-75). 
The outcome of this initial work has been a serious re-evaluation of the overall 
worthiness of the approach and an ongoing examination of how it may be improved. 
The need to quantify (or, at least, to have some idea of the amount of) the SC removed 
is now clear, not only for the reasons already given, but because it is obvious that 
different tapes and different experimentalists will inevitably strip the SC in a variable 
fashion, making inter- and intra-laboratory comparisons impossible.  Even when the 
type of tape is standardized, and an attempt is made to exert an equal pressure on each 
tape applied to the skin (76), the SC amount removed still depends on, for example, 
the speed with which the tape is subsequently removed from the subject and exactly 
where on the forearm the experiment is performed.  As standardization appears very 
difficult to achieve, therefore, it is clearly more sensible to identify a method by 
which the SC removed can be quantified, thereby allowing the uptake of drug into this 
tissue to be normalized (and expressed, for example, as an amount per unit volume, or 
per unit weight, of SC). For the moment, these uncertainties mean that the minimum 
number of subjects required for a bioequivalence study cannot be specified. 
Another, but more invasive (and probably less acceptable) option is to use a 
procedure which removes all the SC at once.  In this case, cyanoacrylate adhesive is 
applied to a glass slide which is then pressed firmly to the skin for about 30 seconds. 
Subsequent removal in one quick movement removes essentially all of the SC in one 
complete sheet (77,78). However, validation of the method for 
bioavailability/bioequivalence studies has not been reported. 
Various approaches to quantify the SC amount removed have been considered 
but, at this time, no single method has achieved universal acceptance.  The most 
straightforward procedure (and, in fact, the one needed to calibrate all others) is to 
weigh each tape-strip before and after SC removal and to determine the amount (m) of 
tissue removed from the difference between these weights.  As the area (A) of SC 
stripped is known, and the density (ρ) of the tissue has been published (5), it is 
possible to convert the SC weight into a depth, or distance (x), into the barrier:  x = 
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m/(A·ρ). Additional standardization is then possible by including in the experimental 
design, concomitant measurements of transepidermal water loss (TEWL) during the 
tape-stripping process (this can be performed either at the drug product application 
site, or at a position adjacent to the treated skin when the formulation contains volatile 
or occlusive excipients that can interfere with the TEWL measurement).  Baseline 
TEWL (TEWL0) across unstripped SC of thickness L is given by Fick’s 1st law of 
diffusion: 
D ⋅ KTEWL0 = ΔCL 
where D and K are the diffusion coefficient of water in the SC, and the SC-viable 
tissue partition coefficient of water, respectively, and ΔC ~1 g·cm-3. After tape-
stripping has removed a depth x of SC, the TEWL will have increased to a new value 
given by: 
D ⋅ KTEWLx = ΔC (L − x) 
Inversion of this second expression yields a linear relationship between (TEWLx)-1 
and x, and the intercept of this line on the x-axis equals the SC thickness (L) (Figure 
5a & 5b) (79). 
With this information in hand, all SC stripping data can now be expressed, not 
in terms of “amount per 10 strips”, or even as amount per volume of SC, but as an 
amount per normalized fraction of SC removed (x/L), a strategy which allows results 
from disparate subjects of different SC thicknesses to be rationalized (Figure 6) (80). 
While this appears to be a sensible, general solution to the problem, it is important to 
point out one caveat: as the tape-stripping procedure and the TEWL measurements 
require a finite amount of time, analysis of the data for rapidly permeating compounds 
may be complicated by the fact that the time to obtain the tape-strips, and to record 
the changes in TEWL, may be similar to the application time, and the drug’s 
concentration gradient may therefore shift during the data collection process (65). 
Other methods to quantify the SC removed by tape-stripping have been 
proposed and demonstrated.  Clearly, the gravimetric approach is not without 
problems (static electricity on the tapes, misleading weights due to uptake of 
formulation excipients, small amounts of SC removed, tediousness, etc.) and a more 
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direct assessment would be useful.  Progress has been made both with respect to the 
use of a protein assay to quantify keratin on the tapes, and via a spectrophotometric 
method evaluating the scattering/absorbance of UV/visible radiation; the latter 
procedure also has the potential to quantify drug on the tape-strip, assuming that an 
absorbance band distinct from those of the SC can be identified.  Both techniques 
have the potential to be more ‘high-throughput’ once sufficiently optimized; however, 
for the moment, neither approach has been perfected, rejection of individual data has 
not been eliminated, and both rely upon the ‘gold standard’ weighing measurement 
for calibration (81-86). Another option, which deserves a final word in this context, is 
the application of infrared spectroscopy (IR), particularly its use in vivo via the 
attenuated total reflectance (ATR) mode.  In this approach, it is possible to semi-
quantitatively assess an IR-active drug (assuming there is at least one absorbance 
within its IR spectrum distinct from those in that of the SC) either on a series of tape-
strips or in the outermost micron or so of SC which has not yet been stripped from the 
skin (44,45,88-91) (Figure 7). 
The method has often been applied to a model permeant, 4-cyanophenol (the 
C≡N (nitrile) absorbance from which is particularly intense and occurs at a frequency 
where the SC is essentially IR-transparent) (64-67), and also to other more relevant 
substances such as the anti-fungal drug, terbinafine (45).  The IR spectrum of SC also 
contains information about the amount of endogenous lipid and protein present as a 
function of depth into the barrier (92), although this feature has not been explored as a 
potentially simple approach to quantify the amount of tissue removed on each tape-
strip. Recent developments in IR imaging coupled with ATR, and the application of 
chemometrics to better “tease out” spectral information, may prove to be useful 
avenues for further research in this regard (93).  However, even supposing the existing 
limitations can be overcome, the principal weakness of IR remains: namely, its 
relative insensitivity compared (for example) to analysis of extracted tape-strip 
samples by HPLC. 
Interpretation of tape-strip data 
When drug and SC are quantified on each tape-strip removed post-treatment of 
the SC, and TEWL measurements have been made to determine SC thickness, it is 
possible to display the concentration of the permeant (Cx) as a function of its relative 
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depth (x/L) into the barrier (Figure 6b). Assuming Fickian diffusion and the 
following boundary conditions:  
▪	 the ‘dose’ of the drug applied is infinite - that is, the drug concentration in the 
vehicle (Cv) remains constant throughout the application time (t);  
▪	 the SC initially contains no drug (Cx = 0 at t = 0); and 
▪	 the viable skin provides a ‘perfect sink’ for the penetrating drug (Cx = 0 at x = L 
for t > 0), 
then the profile is given by (46,64,94): 
∞⎧ ⎫x 2 1 sin(nπ ⋅ x )⋅ exp(− D ⋅ n2 ⋅π 2 ⋅ t )Cx	 = K ⋅ Cv ⋅ ⎨(1− ) − 2 ⎬L π ∑ n L	 L⎩ n=1 ⎭ 
where K is the SC-vehicle partition coefficient of the drug and D is its diffusivity 
through the barrier. When data like those in Figure 6b are fitted with the above 
expression, it is possible to derive two parameters, K and D/L2, which characterize 
drug uptake into the SC from the applied formulation.  These physicochemical 
parameters are relevant to DPK in that they report, respectively, on the extent and the 
rate of drug uptake into the SC: the partition coefficient (K) reflects the relative 
affinity of the drug for the SC compared to the applied formulation and is related to 
the extent of absorption, therefore; the ratio D/L2 has units of [time]-1 and can be 
considered as a first-order rate constant for drug transport through the SC – a measure 
of absorption rate, in other words. Integration of the concentration profile equation 
yields an “area-under-the-curve” (AUC) (46): 
1	 ∞ 2 2⎧1 4 1 ⎛ (2n +1) .π .D.t ⎞⎫AUC = ∫Cxd (x L)= K.Cv ⎨ − 2 ∑ 2 exp⎜⎜− 2 ⎟⎟⎬2	 π n=0 (2n +1) L0 ⎩	 ⎝ ⎠⎭ 
which represents the total amount of drug in the SC at the end of the application 
period (t). Together, K, D/L2 and AUC offer DPK parameters that can be used to 
objectively compare topical drug bioavailabilities from different formulations.  They 
also allow differences in bioavailability to be explained mechanistically; for example, 
to answer the question whether a putative penetration enhancer elicits improved drug 
delivery by increasing partitioning into, or by facilitating diffusion through, the 
barrier. This capability has been illustrated using the anti-fungal drug, terbinafine 
(44) (Figure 8). 
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Finally, it is worth pointing out that once K and D/L2 have been evaluated from 
an experimentally determined Cx versus x/L profile, they can be used with the 
equation above to predict AUC at all other times of application (t).  Providing that the 
parameters do not change with time (which, it must be admitted, is not always the 
case (45), this means that the complete absorption profile of the drug can be derived 
from a relatively short-duration experiment.  Again using terbinafine, some 
preliminary validation of this idea has been achieved (Table 1 (46)).  A more 
extensive effort, with ibuprofen as the delivered drug, has confirmed this earlier 
finding (94). In addition, this data analytical approach has value with respect to 
experimental design; with knowledge of D/L2, the classic lag-time for diffusion 
(L2/6D) across the SC can be calculated, as well as the time necessary to reach steady-
state transport (~2.7 L2/6D) (95). This information should permit more efficient DPK 
studies to be performed with tape-stripping timed to provide the maximum possible 
discrimination, for example, between the different drug products under evaluation. 
Tape-stripping – unresolved issues 
Despite the clear value of a DPK approach based upon tape-stripping, there 
remains work to be done before its usefulness can be fully exploited.  First and 
foremost, the method has to be validated appropriately via clear demonstrations that 
significant differences in drug uptake into normal SC translates into clinically 
distinguishable scenarios in the real world; that is, the hypothesis that the SC 
concentration profile reflects drug availability at the site of action must be confirmed. 
Logically, this will be more straightforward to accomplish with drugs having their site 
of action on or in the SC (e.g., anti-fungals), and it is likely that, at least initially, the 
case will have to be made on a drug class by drug class basis.  Although it is clearly 
expedient to move quickly to an easier approval path for generic topicals, the value 
and relevance of any approach adopted must be recognized by the dermatologist and 
must be seen to translate into a measurable clinical outcome. 
Second, the procedures to be followed, and the DPK protocol itself, have to be 
at least partially standardized.  Quantification of the SC removed is mandatory and 
there is an important need to develop a simple and rapid method for this purpose. 
With such knowledge, complete removal of the SC is not necessary for comparative 
purposes, thereby allowing for a less invasive procedure; further, this means that the 
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method does not have to be restricted to one particular adhesive tape, the choice of 
which can be based on methodological criteria such as ease of drug extraction, 
absence of components that may potentially interfere with the drug assay, and 
allowing removal of the SC with a reasonable number of strips (~10-15).  Cleaning 
the treated area of the SC prior to tape-stripping is important and must be capable of 
removing excess formulation efficiently without inadvertently ‘driving’ drug into the 
barrier. This includes displacement of vehicle from the natural “furrows” in the skin 
(91), the depth of which can be significantly greater than the SC thickness.  Debate 
continues as to whether one or two tape-strips should be taken initially and discarded, 
the argument being that any drug lodged on these layers, even after cleaning the skin, 
would never be absorbed. For the moment, no consensus exists on this point but 
clearly it will be necessary to better define the procedures to be followed when 
cleaning the skin at the end of the application period.  This issue is particularly 
important both for poorly penetrating chemicals (e.g., those of higher molecular 
weight) and for drug products administered in complex vehicles (such as those 
including liposomes or nanoparticles). 
Third, the question of spatial localization of drug must be addressed; 
specifically, it has been recognized that the target for certain drugs may be a skin 
appendage (a hair follicle, or a sebaceous gland, for instance) and that particular 
formulations have been proposed for optimization of delivery to these structures. 
Exactly how tape-stripping might be used to compare vehicles which set out to 
achieve, for example, follicular targeting, has not been demonstrated.  In this case, it 
would be necessary to show that SC levels are correlated with drug amounts in the 
appendage; however, if a formulation did specifically target a follicle, it might be 
logical to think that one would find less drug in the SC as a result. The problem is 
complex, therefore, and may need to call upon application of recent work which has 
attempted to deduce the contribution of follicular transport to total drug delivery by 
comparing SC uptake in normal skin to that in skin whose follicles have been 
physically sealed (96-99). Obviously, further validation is required using drugs and 
drug products designed to act on these appendageal structures. 
Finally, there is the question of the relevance of the DPK approach, which has 
been developed for use on normal skin, to drug performance on diseased skin.  In part, 
this relates to the validation issue discussed above and the need to correlate DPK 
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measurements with clinical outcome. There is also the outstanding unknown as to 
whether DPK, or a modified version thereof, can be adopted for use on diseased 
tissue. It is important to acknowledge, furthermore, that the methodology in its 
present state does not differentiate free and bound drug in the SC. 
Microdialysis 
During the last decade, microdialysis has been shown to be a promising 
technique for the assessment of cutaneous drug delivery (100,101). The technique is 
based on the passive diffusion of compounds down a concentration gradient across a 
semi-permeable membrane forming a thin hollow "tube” (typically a few tenths of a 
millimetre in diameter), which – at least, in theory - functionally represents a 
permeable blood vessel.  Two kinds of probe are in common use: the so-called linear 
and concentric probes (Figure 9a,b). The former is the most prevalent design used 
because it is simple, thinner and inexpensive to manufacture from artificial kidney 
fibres (102-104). The probe is implanted superficially into the dermis or subdermis, 
parallel to the skin surface via a guide cannula. The fibre is slowly perfused with a 
physiological solution, which equilibrates with the extracellular fluid of the 
surrounding tissue, exchanging substances smaller than the cut-off value of the 
membrane. The exchange of material is driven by passive diffusion (105), and the 
microdialysis technique may be used not only to monitor the extracellular 
concentrations of exogenous or endogenous compounds, therefore, but also to deliver 
drugs to a specific target tissue. 
A key feature of microdialysis is its ability to continuously monitor the 
extracellular concentration of a drug in different compartments of the body. Indeed, a 
microdialysis probe can be implanted in virtually any body organ or tissue (106). 
Among the limited number of techniques available for the direct assessment of drug 
concentrations in dermis, cutaneous microdialysis is the only one that allows unbound 
analytes to be sampled.  Hence, microdialysis provides a pharmacokinetic profile, 
with high temporal resolution, of the drug in the target tissue. As the level of unbound 
drug generally determines the pharmacodynamic response, the pharmacological 
relevance of the method is clear.  
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The feasibility of microdialysis to sample a drug in the skin has been 
demonstrated in animals and humans (101,107).  Microdialysis has been shown to be 
useful (i) to assess free drug concentrations in the dermis or subcutaneous tissue, 
depending on probe depth, after topical application of a formulation, (ii) to compare 
different formulations of a drug and assess bioequivalence/bioavailability, and (iii) to 
measure whether therapeutic concentrations are reached in the skin. 
Another important advantage of microdialysis is that no biological fluid is 
removed. In vivo, in man, multiple sampling sites can be simultaneously set up and 
used to determine, for example, drug penetration into the skin and the effect of 
different vehicles (107), cutaneous metabolism (108,109), and the impact of barrier 
disruption (110). This same flexibility has also allowed the impact of probe depth on 
the data obtained to be assessed (111,112), and has allowed the inherent variability of 
the method to be reduced (113). 
The initial research evaluating microdialysis for topical delivery was mostly 
performed in rats, an animal chosen for its ease of handling rather than for its 
suitability as a model for human skin penetration.  Proof-of-concept was established 
with 5-fluorouracil (103), and subsequent work evaluated, inter alia, the impact of 
formulation, the action of penetration enhancers, and the improved delivery possible 
with iontophoresis (111,112,114-122)). A significant effort has also been made to 
correlate microdialysis recovery with barrier perturbation.  Using salicylic acid as a 
model penetrant, uptake was shown to be proportional to barrier function as 
measured, for example, by transepidermal water loss (123), suggesting that the 
technique might be useful for assessing bioavailability in topical dermatoses. 
In humans, the first applications of microdialysis involved the measurement of 
(a) ethanol absorption (124), and (b) cutaneous glucose levels (125,126). 
Subsequently, the transdermal delivery of nicotine released from a commercial patch 
has been investigated (127,128), and some correlation has been found between the 
plasma concentration and perfusate level versus time profiles.  Less success was 
obtained with estradiol, however, with 8 out of 10 experiments revealing no 
detectable estradiol in the dialysate.  Likewise, even after barrier disruption, 
betamethasone 17-valerate, and the highly protein-bound drug, fusidic acid, could not 
be successfully sampled (129).  On the other hand, less hydrophobic and more quickly 
penetrating substances, such as non-steroidal anti-inflammatory drugs, have been 
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monitored easily by cutaneous microdialysis (108,109,111,130-132).  The cutaneous 
penetration of salicylic acid through normal and perturbed skin using microdialysis 
sampling has been shown to be more sensitive than non-invasive bioengineering 
techniques in detecting the effect of acetone treatment. A positive dose-response was 
also found between salicylic acid penetration and the degree of irritant dermatitis 
induced by sodium lauryl sulphate pre-treatment. 
The skin penetration of various salicylate esters and their skin metabolism in 
dermal and subcutaneous tissue has been studied (109). The delivery of topical 
diclofenac was similarly demonstrated following a single application of a gel (130). 
The topical bioequivalence of lidocaine delivery from a microemulsion and from a 
conventional oil-in-water emulsion was assessed pharmacokinetically by 
microdialysis and the results were compared to pharmacodynamic measurements as 
well (106). Furthermore, microdialysis has been used to study iontophoretic delivery 
of propanolol acyclovir and flurbiprofen (111,133,134). Additionally, the role of 
stratum corneum, and of dermal microvasculature perfusion, in the penetration and 
tissue distribution of the water-soluble drugs, acyclovir and pencyclovir, have been 
investigated by cutaneous microdialysis (135). 
Microdialysis is claimed to be minimally invasive, provoking only a minor, 
reversible trauma caused by insertion of the guide cannula when implanting the probe 
(136-138). Moreover, changes in the tissue surrounding the probe may affect the 
recovery and measurement of the analyte.  Therefore, when using the microdialysis 
technique, an equilibration of 60-90 minutes following probe insertion is usually an 
integral part of the protocol (136,137). The effects of the probe insertion can be 
classified as (i) direct trauma to cells and tissues; (ii) modification of blood perfusion 
due to an axon reflex; and (iii) inflammatory or “foreign body” reactions to the probe 
(139). In vivo assessment of the skin after insertion of the microdialysis probe is 
usually performed using non-invasive measurements of TEWL, cutaneous blood flow, 
and histology (136-139). The extent and duration of “trauma” to the skin can be 
modulated by the probe design and the use of a local anaesthetic.  Guide cannulas 
with smaller dimensions generally provoke smaller reactions and the provoked 
increases in local blood flow (and histamine release) subside more quickly; the 
concomitant use of a topical anaesthetic cream can reduce the duration of vascular 
response to less than an hour (140-142).  Longer-term implantation has been studied 
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in animal models and a general inflammatory response observed: infiltration of 
lymphocytes at 8 hours, cell changes and cell attachment to the dialysate membrane at 
24 hours, fibrosis after a week, and scar tissue formation.  However, apart from the 
initial reaction on probe insertion, tissue responses are relatively minor throughout the 
duration of a typical microdialysis experiment (~8 hours) (103,143). 
Method development and optimization 
Since microdialysis operates under non-equilibrium conditions, the 
concentration of analyte in the dialysate is lower than that in the extracellular fluid 
surrounding the probe. Relative recovery has been defined as the ratio of these 
concentrations, and should be independent of the absolute free concentration of the 
compound in the skin (assuming no binding to the dialysis membrane). Several 
approaches have been suggested for determination of the in vivo recovery of the 
analyte by the microdialysis probe: the stop-flow method (144), the extrapolation-to­
zero flow technique (142), the point of no net flux (102), and retrodialysis (145). 
Extensive reviews of the various techniques have been published (105).  Retrodialysis 
is probably faster and more convenient than the other alternatives.  This, “internal 
reference technique” (146,147), introduces a marker into the perfusate and the rate of 
delivery of this compound is measured during the microdialysis experiment. 
Recovery (R) is then determined from:  
R = 100▪(Cin – Cout)/Cin 
where Cin is the concentration of marker perfused into the fibre and Cout is the 
concentration determined in the sample. This method assumes, and/or demonstrates, 
that the recovery efficiency of the target analyte is quantitatively similar to the 
delivery of the retrodialysis marker. It follows that the marker should 
physicochemically resemble, as far as possible, the analyte of interest. An important 
advantage is that fluctuations in the recovery of the probe during the experiment are 
taken into account by continuous retrodialysis of the marker.  Conversely, a 
significant limitation is that the presence of the marker perturbs in some way (e.g., 
competition for binding) the local disposition of the drug.  
The relative recovery is influenced by the probe, the tissue perfused and the 
analyte of interest (100). To increase the relative recovery, the length of the probe and 
its molecular weight cut-off limit should be increased, while perfusate flow should be 
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reduced. Typically, in dermal microdialysis, the probe length is ~1-2 cm, and the flow 
rate between 0.5 and 5 µL/min. The molecular weight cut-off chosen is typically in 
the range of 5 to 20 KDa to avoid protein leakage into the dialysate. For dermal 
microdialysis, the linear probe design is preferred whereas, for subcutaneous 
implantation, both linear and concentric probes have been used. 
Because the dialysis fibre excludes diffusion of proteins, the samples are 
sufficiently purified for further analysis. The principal challenge to the procedure is 
sensitivity, especially for the measurement of (a) lipophilic permeants which are 
slowly and poorly extracted into the microdialysis perfusate, and (b) of compounds 
with a high protein binding. For example, in earlier work, fusidic acid and 
betamethasone-17-valerate were not detectable by microdialysis (129).  Although it 
has been suggested that recovery may be improved by introducing co-solvents (e.g., 
polyethylene glycol), or cyclodextrins, or lipids, into the perfusate, or by changing its 
pH, the advantages of such a strategy must be balanced against potential tissue 
alterations and their impact upon biocompatibility (148,149).  Low rates of perfusion 
(0.5 – 5 μL/min) are mandatory for compounds with low recoveries, especially those 
which are highly protein-bound. Nevertheless, this means that the samples are of low 
volume and contain small absolute amounts of analyte.  The analytical challenge is 
therefore considerable and demands sensitive techniques; HPLC may not be sufficient 
and the use of specific biosensors and mass spectrometry (as well as other techniques) 
has been reported (138,150). 
To validate the use of microdialysis, as a method to assess bioavailability/ 
bioequivalence, a systematic comparison with existing methods is essential. 
Generally speaking, when different formulations of a drug have been compared, 
microdialysis has determined the same rank order as other approaches.  However, the 
absolute, measured amounts of drug absorbed are different (Figure 11).  For example, 
the quantity of drug found in the skin after an in vitro diffusion cell experiment is 
higher than that detected by microdialysis (103). The explanation for this observation 
is that the classic in vitro technique (i) measures both bound and unbound drug and 
(ii) does not reproduce the effects of local blood flow on absorption. 
A particularly positive, and rather unique feature, of microdialysis is that the 
method can be used to evaluate drug permeation across both normal and diseased 
skin. Furthermore, in the same psoriatic patient, penetration at a specific lesion may 
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 be compared to that through unaffected skin. In addition, as well as measuring drug 
concentration, microdialysis may also have the potential to quantify a biomaker, or 
the concentration of another surrogate measure, for therapeutic activity.  Concomitant 
pharmcokinetic and pharmacodynamic evaluations are therefore possible.  
Interpretation of microdialysis data 
It should be emphasized that data from microdialysis experiments can be 
analyzed to yield practical pharmacokinetic parameters.  Cmax, Tmax, absorption 
constant, lag time and AUC can be detemined from the plot of free drug concentration 
in the dermis as a function of time. For example, a one-compartment model has been 
used to differentiate between results from two formulations of lidocaine (110) via 
comparison of absorption rates and lag-times.  In this case, prilocaine was used as a 
retrodialysis calibrator. In another elegant study, cutaneous microdialysis 
demonstrated that the skin/plasma ratio of 8-methoxypsoralen was orders of 
magnitude greater following topical administration of the drug (as compared to oral 
dosing). Evaluation of Cmax in the skin, furthermore, permitted optimization of the 
time of UV irradiation in PUVA therapy (151).  Elsewhere, topical application of the 
antifungal fluconazole resulted in free dermal concentrations below the minimal 
inhibitory concentration (112). This ability to measure whether a therapeutic 
concentration of a drug in the skin has been attained after topical administration is a 
particular advantage of microdialysis. In addition, both the applied drug and any 
metabolites formed by biotransformation in the skin are, in theory, detectable by this 
method.  However, only in a few exceptional circumstances (e.g., salicylate 
derivatives (109)) has significant metabolism been observed. 
The number of subjects necessary for a microdialysis study to determine 
whether two formulations are bioequivalent depends on the degree of variability 
observed in the data. From a practical standpoint, it has been suggested that this 
problem should be tackled by ensuring that each subject acts as its own control (113). 
Under these circumstances, and performing duplicate measurements in every 
volunteer, ~20 subjects are considered sufficient to distinguish two formulations 
within the classic 80-125% confidence interval. In contrast, most microdialysis 
bioequivalence studies in the literature have been performed with 6 to 10 volunteers 
(107,110). 
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Microdialysis – unresolved issues 
While many studies comparing microdialysis to other methods have shown 
reasonable correlation, further validation work is essential if this approach is to be 
recognized by the regulatory agencies as an option for bioavailability and 
bioequivalence assessment. One key issue in the development of a standardized 
protocol is the reproducible insertion of the microdialysis probe to a consistent depth 
within the skin. Probe implantation remains a technical challenge that is only 
mastered with patience and practice.  Although the significance of probe depth on the 
resulting permeation profile is a matter of some debate, it is clear that implantation in 
the either the superficial dermis, or the deep dermis or the subcutaneous tissue can 
have an obvious impact on the data obtained (111,112). 
A further limitation to the routine application of microdialysis, at the present 
time, is analysis of the very low levels of drug in the dialysate.  The most successful 
demonstrations of the approach have been made with compounds which readily 
penetrate the skin and which have decent aqueous solubilities and low protein 
binding. Such molecules are rare, however, and are not always relevant to 
dermatological therapy.  Corticosteroids, on the other hand, the vasoconstriction 
response to which might offer a useful validation ‘marker’ for microdialysis, have 
never been successfully monitored by the technique (presumably due to their low 
permeabilities, poor aqueous solubilities and high protein binding). 
In addition, even though microdialysis may be reasonably termed “minimally 
invasive”, its use in vivo is typically limited to experiments lasting 5 to 10 hours.  For 
slowly permeating drugs, therefore, the quantities absorbed in this time will be 
minimal, and the analytical problems quite daunting. 
Other approaches 
Finally, a few words about some alternative strategies, of which only confocal 
Raman spectroscopy is receiving significant attention at this time. 
Skin biopsy 
Skin biopsy, whether to the level of the dermis (shave biopsy) or through to the 
sub-cutis (punch biopsy), are invasive and generally performed under local 
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anaesthesia. While such methods have a place in dermatological surgery (to remove 
warts and small tumours, for example), their application for tissue sampling and 
analysis post-drug application has not attracted much attention as a routine approach 
for use in vivo. Despite the obvious advantage of offering a ‘snapshot’ of drug 
disposition in the different skin layers, the aggressive nature of the biopsy rules out 
any chance that it might be adopted as a standard procedure.  Even attempts to 
minimize tissue trauma (131,152) fail to render the method remotely acceptable and 
its use in the foreseeable future will be restricted to animal and in vitro studies. 
Suction blister 
Applying a partial negative pressure to the skin disrupts the epidermal-dermal 
junction and forms a blister which fills progressively with interstitial fluid and serum 
(153,154). This liquid offers a pharmacokinetic “compartment”, therefore, in which a 
previously applied drug can be sampled with a hypodermic needle and quantified; if 
multiple blisters are raised (as is possible with certain commercially available 
devices), then a concentration-time profile of the drug in the skin can be obtained. 
While on the surface attractive, this approach is also quite invasive and causes 
obvious scarring, albeit over relatively small areas of skin.  The technique can be used 
to compare topical formulations in a reasonably objective way (155,156), but the 
potential binding of the drug to skin tissue, especially for very lipophilic species, may 
mean that very low levels are present, if at all, in the blister fluid (157).  Taken 
together, this has meant that the procedure has not been widely used and, once again, 
is presently viewed as too invasive for practical and routine application in topical 
bioavailability experiments. 
Follicle delivery 
Drug delivery to the follicle following application of formulations to the skin is 
an established fact. Although the follicles occupy a relatively small fractional area 
(on average, ~0.1%) of the surface, it appears that diffusion via these appendages is 
fast relative to that through intact SC, and probably accounts for the first drug 
molecules which penetrate deep into the skin (158).  Furthermore, the follicle is a 
bona fide target for skin diseases, such as acne and alopecia, and this raises the issue 
of drug bioavailability to this specific structure.  For example, it has been claimed that 
certain particle sizes are optimal for sequestration in the follicle (159) thereby 
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concentrating the drug at this site and subsequently providing a sustained release to 
the local environment.  However, a method, with which to quantify such ‘targeting’, 
has been difficult to validate unequivocally and no approach can be claimed to have 
demonstrated practical utility for quantitative bioavailability/bioequivalence 
assessment to the follicle.  Nevertheless, there have been some innovative ideas 
reported in the literature (77,160,161) and, more recently, somewhat simpler 
methodology has been described, with which the contribution of follicular transport to 
the overall permeation of a drug in vivo in man has been estimated (99,162). 
Confocal Raman spectroscopy 
This technique uses the confocal principle to noninvasively examine the outer 
layers of the skin by Raman spectroscopy.  In this way, it is possible to acquire 
rapidly, in vivo in humans, Raman spectra of the skin as a function of depth (163). 
The method is able to provide, for example, information on the hydration of the SC, 
and the manner in which the water concentration profile across the barrier may be 
altered by the use of moisturizing agents (163-165).  Other analytes, such as urea, can 
also be examined via their unique Raman signature which allows them to be 
differentiated from the spectrum of the skin’s constituents (166). 
The approach is comparable to the application of reflectance infrared 
spectroscopy described earlier.  In distinct contrast, however, confocal Raman does 
not require progressive stripping of the SC to determine the concentration versus 
depth profile of a target substance, and this is clearly an important advantage.  Like 
ATR-IR, however, confocal Raman requires that the molecule of interest be present at 
a sufficient concentration, and possess spectral features of sufficient intensity, to 
permit its differentiation from those of the skin (163).  Therein lies, at present, the 
major drawback of these IR-based techniques.  With confocal Raman, in addition, 
only relative concentrations (rather than absolute levels) can be determined.  It 
remains to be seen, therefore, whether this significant technological development will 
contribute eventually to the evaluation of topical drug bioavailability and/or 
bioequivalence. For the moment, the method offers a unique research tool and a 
novel approach to evaluate skin moisturization. 
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Conclusions 
Despite pressure on regulatory agencies, such as the FDA, there is no generally 
accepted method with which to evaluate the bioavailability and bioequivalence of 
topical drug products. For the present, therefore, with the exception of the 
vasoconstriction assay for corticosteroids, and despite the diversity of efforts which 
have been made (Table 2), clinical studies are obligatory.  Unlike oral administration, 
for example, where the blood level of a drug is a generally accepted ‘surrogate’ for its 
concentration at the site of action, topical drug delivery poses a more complex 
problem.  In this case, the site of action (even when it is known, which is not always 
the case) is not always accessible and a suitable ‘surrogate’, e.g., the SC, has not been 
generally validated. Two approaches are under most intensive scrutiny: one, 
microdialysis, strives to make measurements of the drug in a true “biophase” of the 
skin; the other, tape-stripping, attempts to establish the SC as the ‘surrogate’ sampling 
site.  In both instances, significant progress has been made and proof-of-concept 
demonstrated.  However, the next steps, i.e., optimization of the procedure(s) and 
transition to a useful and practical regulatory test, remain challenges for future work. 
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Figure 1. Correlation between the amount of different chemicals absorbed across skin 
following a 30-minute application and the quantity recovered in SC tape-strips after an 
identical, but independent, administration procedure. Redrawn from reference 52. 
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Figure 2. Schematic representation of a dermatopharmacokinetic (DPK) study to assess 
topical bioequivalence between test and reference formulations containing the same drug. (A) 
In the uptake, or absorption, phase, the SC is tape-stripped immediately after each treatment 
time, and the drug level in the barrier is determined. (B) In the clearance phase, after the 
maximum treatment time, the SC is subsequently stripped after progressively longer periods 
post-removal of the formulations. CTR = control, drug-free formulation. 
37
 
D
ru
g 
le
ve
l 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0 
Reference product 
Test product 
AUC 
Cmax 
Tmax 
0 2 4 6 8 9 24
 
Treatment time (h)
 
Figure 3. DPK profiles of reference and test formulations containing the same drug. The 
parameters to be compared are the maximum drug level in the SC (Cmax), the time at which 
this maximum level is reached (Tmax) and the area under the SC quantity versus time profile 
(AUC). 
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Figure 4. DPK profiles (means of n = 49) of three (0.025% v/v) tretinoin gel products in 
human stratum corneum (SC). Solid line = reference product (Retin-A); dotted line = generic 
formulation; dashed line = Avita gel (redrawn from reference 72). At the time points indicated 
with an asterisk (*), a significant difference between Avita and both the reference and gel 
products exist (analysis of variance, Fisher's protected least significant difference, p < 0.05).  
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Figure 5. (A) Progressive increase of transepidermal water loss (TEWL) as a function of the 
absolute depth (μm) of stratum corneum removed. (B) The data in A, re-plotted as a linear 
relationship between (TEWL)-1 and the depth of SC removed. The x-axis intercept equals the 
SC thickness. 
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Figure 6. A. Increase in transepidermal water loss (TEWL) as a function of the amount of 
SC thickness removed (x) by serial tape-stripping (n = 20). B. Increase in TEWL as a 
function of SC thickness removed (x) normalized by the corresponding intact membrane 
thickness (H) for each individual. 
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Figure 7. Schematic diagram of an attenuated total reflectance (ATR) device mounted on a 
Fourier transform infrared (FTIR) spectrometer. The sampling area of the crystal is made to 
contact with the treated skin site or the tape-strip. IR radiation from the spectrometer is 
deflected by a first mirror to the ATR crystal, in which it undergoes total internal reflection, 
penetrating superficially into the skin, before exiting the crystal and being re-directed to the 
detector. 
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Figure 8. Terbinafine (TBF) concentration versus SC depth profiles in vivo (n=5). The 
individual data points and the best fits of Eq.(1) to the results are shown following application 
(A) in the control formulation (EtOH-IPM, 50:50), and (B) in the same formulation 
containing 5% oleic acid. Redrawn from reference 46. 
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Figure 9. Schematic diagram of two currently used microdialysis probes for DPK 
experiments. In both cases, a semi-permeable dialysis membrane collects the absorbed free 
drug. (A) Single-lumen probe: the membrane is located in the middle of the probe, and the 
perfusate flow is mono-directional. (B) Dual-lumen probe: the membrane is on the tip of the 
probe, and the perfusate flow is bi-directional. 
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Figure 10. Penetration of lidocaine into the dermis of 8 volunteers measured by 
microdialysis (from reference 107)  
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Figure 11. Local availability of ketoprofen applied topically from two gel formulations: 
assessment (a) in vitro in diffusion cells (upper panel), (b) in vivo by tape stripping (middle 
panel), and (c) by dermal microdialysis (lower panel) (A.-R. Denet & V. Préat, unpublished 
data). 
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Table 1. Comparison between the experimentally determined values of AUC 
(mean ± SD; n=4) following 2 and 4 hours of terbinafine application, and the 
predictions based upon K and D/L2 results determined from the data obtained 
after a 30-minute application. Data from reference 45. 
Treatment time (h) Experimental AUC*10 (M) Predicted AUC*10 (M) 
0.5 2.60 ± 1.09 -
2 4.28 ± 1.81 4.76 ± 1.95 a 
4 4.17 ± 1.03 5.21 ± 2.68 a 
a Experimental value is not significantly different (p>0.05) from the corresponding predicted 
result. 
Table 2. Methods to assess drug penetration into and/or across the skin 
 Method Measurea Measurement site Temporal 
resolution 
Technical 
simplicity 
In vitro Diffusion cell Q Transport into and 
across skin 
++ + 
In vivo: non- or 
minimally invasive 
Tape stripping Q Stratum corneum 0 + 
 ATR-FTIR Q Stratum corneum + + 
 Raman Q/L Upper skin + + 
Microdialysis Q (free) Dermis (or subdermis) ++ -
 Vasoconstriction A Microcirculation + +/-
In vivo: invasive Blister Q Extracellular fluid 0 +/-
 Biopsy Q Skin 0 + 
Biopsy Q+L Skin (depth) 0 +/- 
aQ = quantity of drug, A = pharmacological activity of drug, L = drug localization. 
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